Zacks Investment Research upgraded shares of Genmab As (OTCMKTS:GNMSF) from a strong sell rating to a hold rating in a report issued on Wednesday morning.
According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “
Separately, JPMorgan Chase & Co. lowered Genmab As from an overweight rating to a neutral rating in a research note on Friday, October 6th.
Shares of Genmab As (OTCMKTS GNMSF) opened at $176.25 on Wednesday. Genmab As has a twelve month low of $163.00 and a twelve month high of $239.75. The company has a market capitalization of $10,473.89, a P/E ratio of 60.99 and a beta of 0.96.
TRADEMARK VIOLATION WARNING: This story was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://transcriptdaily.com/2018/01/06/genmab-as-gnmsf-upgraded-at-zacks-investment-research.html.
Genmab As Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genmab As Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab As and related companies with MarketBeat.com's FREE daily email newsletter.